The stock of Ascendis Pharma A/S ADR (ASND) has gone down by -1.79% for the week, with a -4.63% drop in the past month and a -10.49% drop in the past quarter. The volatility ratio for the week is 3.47%, and the volatility levels for the past 30 days are 3.58% for ASND. The simple moving average for the last 20 days is -2.26% for ASND’s stock, with a simple moving average of -9.40% for the last 200 days.
Is It Worth Investing in Ascendis Pharma A/S ADR (NASDAQ: ASND) Right Now?
Additionally, the 36-month beta value for ASND is 0.65. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ASND is 56.61M and currently, short sellers hold a 6.02% ratio of that float. The average trading volume of ASND on November 15, 2024 was 610.46K shares.
ASND) stock’s latest price update
Ascendis Pharma A/S ADR (NASDAQ: ASND)’s stock price has gone decline by -1.39 in comparison to its previous close of 126.03, however, the company has experienced a -1.79% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that – YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3
Analysts’ Opinion of ASND
Many brokerage firms have already submitted their reports for ASND stocks, with Oppenheimer repeating the rating for ASND by listing it as a “Outperform.” The predicted price for ASND in the upcoming period, according to Oppenheimer is $180 based on the research report published on September 05, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see ASND reach a price target of $175, previously predicting the price at $156. The rating they have provided for ASND stocks is “Buy” according to the report published on June 25th, 2024.
Stifel gave a rating of “Buy” to ASND, setting the target price at $200 in the report published on May 31st of the current year.
ASND Trading at -5.96% from the 50-Day Moving Average
After a stumble in the market that brought ASND to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.81% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 3.47%, as shares sank -1.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.44% upper at present.
During the last 5 trading sessions, ASND fell by -1.79%, which changed the moving average for the period of 200-days by -4.35% in comparison to the 20-day moving average, which settled at $127.15. In addition, Ascendis Pharma A/S ADR saw -1.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ASND
Current profitability levels for the company are sitting at:
- -1.11 for the present operating margin
- 0.86 for the gross margin
The net margin for Ascendis Pharma A/S ADR stands at -1.54. The total capital return value is set at 3.93. Equity return is now at value -867.62, with -61.92 for asset returns.
Based on Ascendis Pharma A/S ADR (ASND), the company’s capital structure generated 1.91 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at -2.1. The interest coverage ratio of the stock is -2.72.
Currently, EBITDA for the company is -438.17 million with net debt to EBITDA at -1.23. When we switch over and look at the enterprise to sales, we see a ratio of 22.59. The receivables turnover for the company is 3.94for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Ascendis Pharma A/S ADR (ASND) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
